Search

Your search keyword '"Seker, Mesut"' showing total 364 results
Start Over Author "Seker, Mesut"
364 results on '"Seker, Mesut"'

6. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Strasser, Simone, Thompson, Alexander, Roohullah, Aflah, Sievert, William, Andelkovic, Vladimir, Knox, Jennifer, Davies, Janine, Asselah, Jamil, Brahmania, Mayur, Majeed, Habeeb, Villanueva, Luis, Yanez Weber, Patricio, Garrido, Marcelo, Pizarro, Gonzalo Ignacio, Yanez, Nicolas, Xu, Ruocai, Ou, Shuangyan, Ren, Zhenggang, Pan, Hongming, Meng, Zhiqiang, Gu, Kangsheng, Chen, Xi, Zhang, Tao, Hao, Chunyi, Cao, Peiguo, Guo, Yabing, Qin, Shukui, Xiao, Juxiang, Fang, Weijia, Wang, Xin, Bai, Yuxian, Chen, Xiaoming, Yan, Dong, Zhao, Hong, Ying, Jieer, Bonilla, Carlos, Urrego, Olga, Zambrano, Angela, Lema, Mauricio, Restrepo Gutierrez, Juan Carlos, Cardona, Andres, Franco Millan, Sandra, Oscar, Madiedo, Ramos, Victor, Merle, Philippe, LeSourd, Samuel, Edeline, Julien, Bronowicki, Jean-Pierre, Bourliere, Marc, Cattan, Stephane, Bouattour, Mohamed, Mineur, Laurent, Regnault, Helene, Dauvois, Barbara, Schulze, Kornelius, Folprecht, Gunnar, Geier, Andreas, Waidmann, Oliver, Finkelmeier, Fabian, Venerito, Marino, Berres, Marie-Luise, Berg, Thomas, Lange, Christian, Schmidt, Hartmut, Waldschmidt, Dirk T, Bitzer, Michael, McDermott, Ray, Duffy, Austin, Masi, Gianluca, Zagonel, Vittorina, Tonini, Giuseppe, Piscaglia, Fabio, Gori, Stefania, Rizzo, Mimma, Biscaldi, Elisa, Foltran, Luisa, Cabibbo, Giuseppe, Ikeda, Masafumi, Kudo, Masatoshi, Aikata, Hiroshi, Numata, Kazushi, Marusawa, Hiroyuki, Kato, Naoya, Kurosaki, Masayuki, Morimoto, Manabu, Yamashita, Tatsuya, Koga, Hironori, Masaki, Tsutomu, Tateishi, Ryosuke, Inaba, Yoshitaka, Arakawa, Tomohiro, Suzuki, Yoshiyuki, Akua, Norio, Kobayashi, Masahiro, Hosaka, Tetsuya, Nakamuta, Makoto, Oza, Noriko, Kondo, Shunsuke, Furuse, Junji, Nagashima, Fumio, Kitano, Masayuki, Takaguchi, Koichi, Ryoo, Baek-Yeol, Lim, Ho Yeong, Kim, Jee Hyun, Kim, Tae-You, Kim, Han Sang, Hernandez Hernandez, Carlos, Motola Kuba, Daniel, Segura Gonzalez, Manuel, Cabrera Luviano, Jesus, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Silva-Bravo, Fernando, Gane, Edward, Stedman, Catherine, Kwiatkowski, Mariusz, Wyrwicz, Lucjan, Nowakowska-Zajdel, Ewa, Kraj, Leszek, Janczewska, Ewa, Surma-Wlodarczyk, Renata, Breder, Valeriy, Sekacheva, Marina, Orlova, Rashida, Vasilyev, Alexander, Zukov, Ruslan, Vladimirov, Vladimir, Minguez, Beatriz, Matilla Pena, Ana, Fernandez Castroagudin, Javier, Romero Gomez, Manuel, Luis Lledo, Jose, Rubin, Angel, Garcia Sanchez, Araceli, Calleja Panero, Jose, Yu, Ming-Chin, Shen, Ying-Chun, Huang, Yi-Hsiang, Jeng, Long-Bin, Chang, Ting-Tsung, Yang, Sheng-Shun, Chen, Shinn-Cherng, Dechaphunkul, Arunee, Tanwandee, Tawesak, Leerapun, Apinya, Seker, Mesut, Harputluoglu, Hakan, Cicin, Irfan, Oksuzoglu, Berna, Bilici, Mehmet, Sezgin Goksu, Sema, Artac, Mehmet, Cil, Timucin, Yalcin, Suayib, Meyer, Tim, Sarker, Debashis, Rao, Ankit, Palmer, Daniel, Evans, Jeff, Hubner, Richard, Finn, Richard, Ulahannan, Susanna, Zakari, Ahmed, Feun, Lynn, Al-Rajabi, Raed, Sung, Max, He, Aiwu, Kardosh, Adel, Goyal, Lipika, Li, Daneng, Choi, Minsig, Posada, Juan, Dodlapati, Jyothi, Shroff, Rachna, Agrawal, Saurabh, Gopaluni, Srivalli, Akce, Mehmet, Alese, Olatunji, Baron, Ari, Dunne, Richard, Loaiza-Bonilla, Arturo, Frenette, Catherine, Llovet, Josep M, Kumada, Hiromitsu, Cheng, Ann-Lii, Galle, Peter R, Kaneko, Shuichi, Wang, Anran, Mody, Kalgi, Dutcus, Corina, Dubrovsky, Leonid, Siegel, Abby B, and Finn, Richard S

Published
2023
Full Text
View/download PDF

10. Pretreatment HALP Score Predicts Prognosis in Patients with Esophageal Cancer Treated with Chemoradiotherapy.

Author

İşleyen, Zehra Sucuoğlu, Beşiroğlu, Mehmet, Şimşek, Melih, Yasin, Ayşe İrem, Topçu, Atakan, Akçakaya, Adem, Seker, Mesut, and Türk, Hacı Mehmet

Subjects
SQUAMOUS cell carcinoma, PEARSON correlation (Statistics), RECEIVER operating characteristic curves, RADIOPHARMACEUTICALS, HEMOGLOBINS, DEOXY sugars, CHEMORADIOTHERAPY, LYMPHOCYTES, CANCER patients, RETROSPECTIVE studies, DESCRIPTIVE statistics, POSITRON emission tomography computed tomography, CHI-squared test, BLOOD platelets, KAPLAN-Meier estimator, LOG-rank test, STATISTICS, ALBUMINS, PROGRESSION-free survival, DATA analysis software, SURVIVAL analysis (Biometry), CONFIDENCE intervals, ESOPHAGEAL cancer, OVERALL survival
Abstract

Objectives: We aimed to evaluate the relation of the pre-treatment hemoglobin-albumin-lymphocyte-platelet (HALP) score with survival and prognosis of locally advanced esophageal squamous cell carcinoma (ESCC) patients receiving chemoradiotherapy (CRT). Methods: We retrospectively included 45 patients with esophageal squamous cell carcinoma who were treated with chemoradiotherapy. The HALP score was calculated as hemoglobin level (g/L)*albumin level (g/L)*lymphocyte count (/L)/platelet count(/L). Results: According to the receiver operating characteristic (ROC) curve, the median of the HALP score was 42.36. According to this value, the patients were divided into two groups; Group 1 included 28 patients who had a HALP score <42.36 and Group 2 included 17 patients who had a HALP score >42.36. Median OS was 20.5 months in Group 1 and the median OS was not reached in Group 2 (p=0.033). Median PFS in all patient groups was 15.2 months. The median PFS was 12.2 months in Group 1 and 30.9 months in Group 2 (p=0.127). Univariate Cox regression analysis showed that pre-treatment low levels of HALP were associated with a short median time of OS (p=0.042). Conclusion: Our study suggested that pretreatment low HALP score was associated with poor OS in patients with locally advanced ESCC who were treated with CRT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Is Clinical Risk Score a Useful Predictive Marker of Early Recurrence Among Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors?

Author

Oven, Bala Basak, Okten, Ilker Nihat, Bilici, Ahmet, Yasin, Ayse Irem, Koca, Sinan, Yuzugullu, Ezgi, Celik, Serkan, Kutlu, Yasin, Seker, Mesut, Simsek, Eda Tanrikulu, and Gumus, Mahmut

Subjects
BREAST cancer prognosis, PROTEIN kinase inhibitors, RISK assessment, CANCER relapse, PREDICTION models, HORMONE receptor positive breast cancer, BREAST tumors, TUMOR markers, CHI-squared test, DESCRIPTIVE statistics, METASTASIS, GENE expression, KAPLAN-Meier estimator, HORMONE therapy, ONCOGENES, STATISTICS, PROGRESSION-free survival, DATA analysis software, DISEASE risk factors
Abstract

Objectives: The addition of CDK4/6 inhibitors to standard hormonotherapy improved progression-free survival(PFS) of hormone-positive, HER-2 negative metastatic breast cancer(mBC). We analyzed clinicopathological risk factors predicting early recurrence in mBC patients treated with a combination of CDK4/6 inhibitor and hormonotherapy. Methods: 229 patients were included, and 95 recurrences were seen. Median ER and PR expressions, ki67 levels, metastatic sites, number of metastasis, and grade were related to recurrence. Patients were classified according to the presence of prognostic factors: group 1 included patients with 0-1 risk factors, group 2 with 2-3 risk factors, and group 3 with ≥4risk factors. Results: Median ER, PR, and ki67 levels were 90, 60, and 25,respectively. Median ER, PR, Kİ67, grade, metastatic site, and the number of metastasis were related to PFS. Advanced CDK4/6 line and response were significant for PFS.Median PFS was 6.5 months for recurrent patients. According to the predictive model, patients who recurred before 6.5 months had a high-risk group (group 2,3). PS, family history, CDK4/6 inhibitor types were found to be related to PFS among the recurrent group. Conclusion: There is a need for a prospective design study to determine the clinicopathological markers identifying early recurrence under CDK4/6 inhibitors so new combination therapies or alternatives can be developed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Llovet, Josep M, primary, Kudo, Masatoshi, additional, Merle, Philippe, additional, Meyer, Tim, additional, Qin, Shukui, additional, Ikeda, Masafumi, additional, Xu, Ruocai, additional, Edeline, Julien, additional, Ryoo, Baek-Yeol, additional, Ren, Zhenggang, additional, Masi, Gianluca, additional, Kwiatkowski, Mariusz, additional, Lim, Ho Yeong, additional, Kim, Jee Hyun, additional, Breder, Valeriy, additional, Kumada, Hiromitsu, additional, Cheng, Ann-Lii, additional, Galle, Peter R, additional, Kaneko, Shuichi, additional, Wang, Anran, additional, Mody, Kalgi, additional, Dutcus, Corina, additional, Dubrovsky, Leonid, additional, Siegel, Abby B, additional, Finn, Richard S, additional, Strasser, Simone, additional, Thompson, Alexander, additional, Roohullah, Aflah, additional, Sievert, William, additional, Andelkovic, Vladimir, additional, Knox, Jennifer, additional, Davies, Janine, additional, Asselah, Jamil, additional, Brahmania, Mayur, additional, Majeed, Habeeb, additional, Villanueva, Luis, additional, Yanez Weber, Patricio, additional, Garrido, Marcelo, additional, Pizarro, Gonzalo Ignacio, additional, Yanez, Nicolas, additional, Ou, Shuangyan, additional, Pan, Hongming, additional, Meng, Zhiqiang, additional, Gu, Kangsheng, additional, Chen, Xi, additional, Zhang, Tao, additional, Hao, Chunyi, additional, Cao, Peiguo, additional, Guo, Yabing, additional, Xiao, Juxiang, additional, Fang, Weijia, additional, Wang, Xin, additional, Bai, Yuxian, additional, Chen, Xiaoming, additional, Yan, Dong, additional, Zhao, Hong, additional, Ying, Jieer, additional, Bonilla, Carlos, additional, Urrego, Olga, additional, Zambrano, Angela, additional, Lema, Mauricio, additional, Restrepo Gutierrez, Juan Carlos, additional, Cardona, Andres, additional, Franco Millan, Sandra, additional, Oscar, Madiedo, additional, Ramos, Victor, additional, LeSourd, Samuel, additional, Bronowicki, Jean-Pierre, additional, Bourliere, Marc, additional, Cattan, Stephane, additional, Bouattour, Mohamed, additional, Mineur, Laurent, additional, Regnault, Helene, additional, Dauvois, Barbara, additional, Schulze, Kornelius, additional, Folprecht, Gunnar, additional, Geier, Andreas, additional, Waidmann, Oliver, additional, Finkelmeier, Fabian, additional, Venerito, Marino, additional, Berres, Marie-Luise, additional, Berg, Thomas, additional, Lange, Christian, additional, Schmidt, Hartmut, additional, Waldschmidt, Dirk T, additional, Bitzer, Michael, additional, McDermott, Ray, additional, Duffy, Austin, additional, Zagonel, Vittorina, additional, Tonini, Giuseppe, additional, Piscaglia, Fabio, additional, Gori, Stefania, additional, Rizzo, Mimma, additional, Biscaldi, Elisa, additional, Foltran, Luisa, additional, Cabibbo, Giuseppe, additional, Aikata, Hiroshi, additional, Numata, Kazushi, additional, Marusawa, Hiroyuki, additional, Kato, Naoya, additional, Kurosaki, Masayuki, additional, Morimoto, Manabu, additional, Yamashita, Tatsuya, additional, Koga, Hironori, additional, Masaki, Tsutomu, additional, Tateishi, Ryosuke, additional, Inaba, Yoshitaka, additional, Arakawa, Tomohiro, additional, Suzuki, Yoshiyuki, additional, Akua, Norio, additional, Kobayashi, Masahiro, additional, Hosaka, Tetsuya, additional, Nakamuta, Makoto, additional, Oza, Noriko, additional, Kondo, Shunsuke, additional, Furuse, Junji, additional, Nagashima, Fumio, additional, Kitano, Masayuki, additional, Takaguchi, Koichi, additional, Kim, Tae-You, additional, Kim, Han Sang, additional, Hernandez Hernandez, Carlos, additional, Motola Kuba, Daniel, additional, Segura Gonzalez, Manuel, additional, Cabrera Luviano, Jesus, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Silva-Bravo, Fernando, additional, Gane, Edward, additional, Stedman, Catherine, additional, Wyrwicz, Lucjan, additional, Nowakowska-Zajdel, Ewa, additional, Kraj, Leszek, additional, Janczewska, Ewa, additional, Surma-Wlodarczyk, Renata, additional, Sekacheva, Marina, additional, Orlova, Rashida, additional, Vasilyev, Alexander, additional, Zukov, Ruslan, additional, Vladimirov, Vladimir, additional, Minguez, Beatriz, additional, Matilla Pena, Ana, additional, Fernandez Castroagudin, Javier, additional, Romero Gomez, Manuel, additional, Luis Lledo, Jose, additional, Rubin, Angel, additional, Garcia Sanchez, Araceli, additional, Calleja Panero, Jose, additional, Yu, Ming-Chin, additional, Shen, Ying-Chun, additional, Huang, Yi-Hsiang, additional, Jeng, Long-Bin, additional, Chang, Ting-Tsung, additional, Yang, Sheng-Shun, additional, Chen, Shinn-Cherng, additional, Dechaphunkul, Arunee, additional, Tanwandee, Tawesak, additional, Leerapun, Apinya, additional, Seker, Mesut, additional, Harputluoglu, Hakan, additional, Cicin, Irfan, additional, Oksuzoglu, Berna, additional, Bilici, Mehmet, additional, Sezgin Goksu, Sema, additional, Artac, Mehmet, additional, Cil, Timucin, additional, Yalcin, Suayib, additional, Sarker, Debashis, additional, Rao, Ankit, additional, Palmer, Daniel, additional, Evans, Jeff, additional, Hubner, Richard, additional, Finn, Richard, additional, Ulahannan, Susanna, additional, Zakari, Ahmed, additional, Feun, Lynn, additional, Al-Rajabi, Raed, additional, Sung, Max, additional, He, Aiwu, additional, Kardosh, Adel, additional, Goyal, Lipika, additional, Li, Daneng, additional, Choi, Minsig, additional, Posada, Juan, additional, Dodlapati, Jyothi, additional, Shroff, Rachna, additional, Agrawal, Saurabh, additional, Gopaluni, Srivalli, additional, Akce, Mehmet, additional, Alese, Olatunji, additional, Baron, Ari, additional, Dunne, Richard, additional, Loaiza-Bonilla, Arturo, additional, and Frenette, Catherine, additional

Published
2023
Full Text
View/download PDF

14. Differentiation of lung and breast cancer brain metastases: Comparison of texture analysis and deep convolutional neural networks

Author

Gultekin, Mehmet Ali, primary, Peker, Abdusselim Adil, additional, Oktay, Ayse Betul, additional, Turk, Haci Mehmet, additional, Cesme, Dilek Hacer, additional, Shbair, Abdallah T. M., additional, Yilmaz, Temel Fatih, additional, Kaya, Ahmet, additional, Yasin, Ayse Irem, additional, Seker, Mesut, additional, Mayadagli, Alpaslan, additional, and Alkan, Alpay, additional

Published
2023
Full Text
View/download PDF

16. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Author

Goktas Aydin, Sabin, primary, Kavak, Engin Eren, additional, Topcu, Atakan, additional, Bayramgil, Ayberk, additional, Akgul, Fahri, additional, Kahraman, Seda, additional, Aykan, Musa Baris, additional, Altıntas, Yunus Emre, additional, Helvaci, Kaan, additional, Urun, Yuksel, additional, Bilici, Ahmet, additional, Seker, Mesut, additional, Sendur, Mehmet Ali Nahit, additional, Olmez, Omer Fatih, additional, Acikgoz, Ozgur, additional, and Cicin, Irfan, additional

Published
2023
Full Text
View/download PDF

17. The Correlation Between Skeletal Muscle Index and Anxiety in Patients with Lung Cancer on the First Day of Chemotherapy

Author

Topcu, Atakan, primary, Yurtsever, Ismail, additional, Isleyen, Zehra Sucuoglu, additional, Besiroglu, Mehmet, additional, Yasin, Ayse Irem, additional, Topcu, Zeynep Alaca, additional, Shbair, Abdallah TM, additional, Toluk, Ozlem, additional, Simsek, Melih, additional, Seker, Mesut, additional, and Turk, Haci Mehmet, additional

Published
2023
Full Text
View/download PDF

22. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

Author

Goktas Aydin, Sabin, primary, Cakan Demirel, Burcin, additional, Bilici, Ahmet, additional, Topcu, Atakan, additional, Aykan, Musa Barış, additional, Kahraman, Seda, additional, Akbıyık, Ilgın, additional, Atci, Muhammed Mustafa, additional, Olmez, Omer Fatih, additional, Yaren, Arzu, additional, Sendur, Mehmet Ali Nahit, additional, Geredeli, Caglayan, additional, Seker, Mesut, additional, Urun, Yuksel, additional, Karadurmus, Nuri, additional, and Aydin, Ahmet, additional

Published
2022
Full Text
View/download PDF

23. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Author

Bilici, Ahmet, primary, Olmez, Omer Fatih, additional, Sezer, Ahmet, additional, Oksuzoglu, Berna, additional, Kaplan, Muhammet Ali, additional, Karadurmus, Nuri, additional, Cubukcu, Erdem, additional, Sendur, Mehmet A.N., additional, Aksoy, Sercan, additional, Erdem, Dilek, additional, Basaran, Gul, additional, Cakar, Burcu, additional, Seker, Mesut, additional, Arslan, Cagatay, additional, Sezgin Goksu, Sema, additional, Cicin, Irfan, additional, Gumus, Mahmut, additional, Selcukbiricik, Fatih, additional, Harputluoglu, Hakan, additional, and Helvaci, Kaan, additional

Published
2022
Full Text
View/download PDF

26. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

Author

Yasin, Ayse Irem, primary, Aydin, Sabin Göktas, additional, Sümbül, Bilge, additional, Koral, Lokman, additional, Şimşek, Melih, additional, Geredeli, Çağlayan, additional, Öztürk, Akın, additional, Perkin, Perihan, additional, Demirtaş, Derya, additional, Erdemoglu, Engin, additional, Hacıbekiroglu, İlhan, additional, Çakır, Emre, additional, Tanrıkulu, Eda, additional, Çoban, Ezgi, additional, Ozcelik, Melike, additional, Çelik, Sinemis, additional, Teker, Fatih, additional, Aksoy, Asude, additional, Fırat, Sedat T, additional, Tekin, Ömer, additional, Kalkan, Ziya, additional, Türken, Orhan, additional, Oven, Bala B, additional, Dane, Faysal, additional, Bilici, Ahmet, additional, Isıkdogan, Abdurrahman, additional, Seker, Mesut, additional, Türk, Hacı M, additional, and Gümüş, Mahmut, additional

Published
2022
Full Text
View/download PDF

27. Metastatic renal hemangiopericytoma: A rare case report

Author

Yaylaci Mustafa, Gumus Mahmut, Salepci Taflan, Celik Erkan, Igdem Akyildiz Aysenur, Salman Tarik, Seker Mesut, Ustaalioglu Oven Basak Bala, and Bilici Ahmet

Subjects
Hemangiopericytoma, Kidney Neoplasms, Neoplasm Metastasis, Antineoplastic Agents, Radiotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

The hemangiopericytoma (HPC) of the kidney is extremely rare perivascular neoplasm. There are no specific radiological or clinical findings that can aid in preoperative diagnosis. In the world literature, only 41 cases of renal HPC have been previously documented. We report on a 56-year old woman with renal HPC of the right kidney who had lung metastasis at the time of diagnosis. The right radical nephrectomy was performed and the combination chemotherapy was given, postoperatively. After 3 cycles of chemotherapy, disease was stable, but progression was seen at the end of 6 courses of chemotherapy. The patient died due to progression of disease ten months later after the diagnosis. We suggested that for patients present with renal mass, renal HPC as well as the other renal tumors should be considered in the differential diagnosis.

Published
2009
Full Text
View/download PDF

29. sj-pdf-1-opp-10.1177_10781552211027931 - Supplemental material for A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer

Author

Topcu, Atakan, Yasin, Ayse Irem, Shbair, Abdallah TM, Besiroglu, Mehmet, Simsek, Melih, Sucuoglu, Zehra, Yurtsever, Ismail, Gucin, Zuhal, Seker, Mesut, and Turk, Haci Mehmet

Subjects
FOS: Clinical medicine, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-1-opp-10.1177_10781552211027931 for A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer by Atakan Topcu, Ayse Irem Yasin, Abdallah TM Shbair, Mehmet Besiroglu, Melih Simsek, Zehra Sucuoglu, Ismail Yurtsever, Zuhal Gucin, Mesut Seker and Haci Mehmet Turk in Journal of Oncology Pharmacy Practice

Published
2021
Full Text
View/download PDF

30. sj-pdf-2-opp-10.1177_10781552211027931 - Supplemental material for A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer

Author

Topcu, Atakan, Yasin, Ayse Irem, Shbair, Abdallah TM, Besiroglu, Mehmet, Simsek, Melih, Sucuoglu, Zehra, Yurtsever, Ismail, Gucin, Zuhal, Seker, Mesut, and Turk, Haci Mehmet

Subjects
FOS: Clinical medicine, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-2-opp-10.1177_10781552211027931 for A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer by Atakan Topcu, Ayse Irem Yasin, Abdallah TM Shbair, Mehmet Besiroglu, Melih Simsek, Zehra Sucuoglu, Ismail Yurtsever, Zuhal Gucin, Mesut Seker and Haci Mehmet Turk in Journal of Oncology Pharmacy Practice

Published
2021
Full Text
View/download PDF

33. Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients

Author

Elkiran, Emin Tamer, Kaplan, Mehmet Ali, Sevinc, Alper, Aksoy, Sercan, Demirci, Umut, Seker, Mesut, Harputluoglu, Hakan, Ozdemir, Nuriye Yildirim, Isik, Feridun, Ulas, Arife, Inanc, Mevlude, Arslan, Ulku Yalcintas, Dogu, Gamze Gokoz, Isikdogan, Abdurrahman, Buyukberber, Suleyman, and Anatolian Society of Medical Oncology Group

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results